B of A Securities Reinstates Neutral on AllianceBernstein Holding, Announces $45 Price Target
B of A Securities analyst Craig Siegenthaler reinstates AllianceBernstein Holding (NYSE:AB) with a Neutral and announces $45 price target.
B of A Securities Reinstates Neutral on Patria Investments, Announces $17 Price Target
B of A Securities analyst Craig Siegenthaler reinstates Patria Investments (NASDAQ:PAX) with a Neutral and announces $17 price target.
Truist Securities Assumes Privia Health Group at Buy, Raises Price Target to $54
Truist Securities analyst Jailendra Singh assumes Privia Health Group (NASDAQ:PRVA) with a Buy rating and raises Price Target to $54.
Raymond James Initiates Coverage On Aya Gold & Silver with Outperform Rating, Announces Price Target of C$9
Raymond James analyst Craig Stanley initiates coverage on Aya Gold & Silver (TSX:AYA) with a Outperform rating and announces Price Target of C$9.
Truist Securities Initiates Coverage On Hims & Hers Health with Hold Rating, Announces Price Target of $7
Truist Securities analyst Jailendra Singh initiates coverage on Hims & Hers Health (NYSE:HIMS) with a Hold rating and announces Price Target of $7.
Alliance Global Partners Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $20
Alliance Global Partners analyst James Molloy initiates coverage on Quoin Pharmaceuticals (NASDAQ:QNRX) with a Buy rating and announces Price Target of $20.
Credit Suisse Initiates Coverage On Tritium DCFC with Neutral Rating, Announces Price Target of $8
Credit Suisse analyst Maheep Mandloi initiates coverage on Tritium DCFC (NASDAQ:DCFC) with a Neutral rating and announces Price Target of $8.
Mizuho Assumes Axsome Therapeutics at Buy, Announces Price Target of $76
Mizuho analyst Graig Suvannavejh assumes Axsome Therapeutics (NASDAQ:AXSM) with a Buy rating and announces Price Target of $76.
Truist Securities Initiates Coverage On Accolade with Buy Rating, Announces Price Target of $15
Truist Securities analyst Jailendra Singh initiates coverage on Accolade (NASDAQ:ACCD) with a Buy rating and announces Price Target of $15.
Truist Securities Initiates Coverage On R1 RCM with Buy Rating, Announces Price Target of $29
Truist Securities analyst Jailendra Singh initiates coverage on R1 RCM (NASDAQ:RCM) with a Buy rating and announces Price Target of $29.